RENETX BIO ANNOUNCES INITIATION OF PATIENT DOSING IN THE FIRST PHASE 1 CLINICAL TRIAL OF FUSION PROTEIN
|
|
Murphy Highlights New Haven's ReNetX Bio as "Murphy's Innovator of the Month"
WASHINGTON, June 28, 2019 -- U.S. Senator Chris Murphy (D-Conn.) announced on Friday that ReNetX Bio, a biotechnology company in New Haven, has been named “Innovator of the Month.” Read More
ReNetX Bio, Inc. Announces U.S. FDA Authorization to Proceed for IND Application to Treat Patients with Chronic Spinal Cord Injury
NEW HAVEN, Conn., June 19, 2019 (PRNewswire) -- ReNetX Bio has announced that the U.S. Food and Drug Administration (FDA) has allowed the Company's Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204. Recruitment will begin immediately for the Phase 1 first-in-human trial of AXER-204 for the treatment of chronic spinal cord injury (SCI). Read More
Raising Awareness for Spinal Cord Injury Research
The Lancet Neurology 17.7 (2018): 581-582
The last annual Wings for Life World Run, a charity event to increase public awareness for spinal cord injury research, was held on May 6, 2018. Read More
The last annual Wings for Life World Run, a charity event to increase public awareness for spinal cord injury research, was held on May 6, 2018. Read More
New Haven-Based ReNetX Bio, Inc. Closes Series A Funding and Expands Upon New Haven Roots
NEW HAVEN, Conn. MAY 07, 2018 (PRWEB) -- The Economic Development Corporation of New Haven announced today that New Haven-based ReNetX Bio, Inc., a private biotech company, has closed on its Series A funding and also solidified the relationship that the company has had with the city. The company plans to begin clinical trials on its drug within the year. Read More
ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium
NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been invited to present as part of a “Clinical Trials 360” symposium at the upcoming American Spinal Cord Injury Association (ASIA) meeting. Read More
Remedy Pharmaceuticals Co-founder and CEO Brings Clinical Trial and Company-Building Experience to ReNetX Bio Advisory Board
NEW HAVEN, Conn., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Sven Jacobson will be the first to admit that developing a new therapeutic for spinal cord injury is a challenging road. But the latest member of the ReNetX Advisory Board sees the promise of their first-in-class therapeutic in development to treat chronic spinal cord injury, and has the experience to help guide the clinical studies needed to move that drug forward. Read More
ReNetX Bio Receives $7M Commitment from Wings for Life to BringSpinal Cord Treatment to Trial
NEW HAVEN, Conn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- The Wings for Life foundation has made a significant commitment to ReNetX Bio, a New-Haven, Conn. based biotech startup that is advancing a cutting-edge therapy for chronic spinal cord injury to clinical trial. The foundation’s support is a testament to the promising research results from ReNetX Founder and Scientific Advisor Stephen Strittmatter, MD, PhD, Vincent Coates Professor of Neurology at Yale. His discovery of proteins which limit nerve fiber growth after injury, and subsequent development of a molecule to block receptors for these proteins, have formed the basis of a therapeutic that offers the first real hope to patients with chronic spinal cord injury. Read More
Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory Board with key opinion leaders specializing in spinal cord injury. Read More
New Spinal Cord Injury Repair Company Launched
Based on an innovative technology from Yale University which has shown promise to grow nerve fibers naturally and restore all facets of nerve function, a new company, ReNetX Bio (formerly known as Axerion Therapeutics), has been launched. Read More on Page 19 of This Week Orthopedics
Yale Scientist Aiming To Reverse Spinal Cord Injuries
NEW HAVEN, Conn., July 27, 2017 -- A Yale neurology and neuroscience professor who hopes to regrow neurons in patients with spinal cord injuries has secured enough funding for a human clinical trial. Read More
Drug Aims to Help Treat Spinal Cord Injuries
NEW HAVEN, Conn., July 25, 2017 -- Researchers at ReNetX Bio are hoping a new name, the potential for a new influx of cash on the horizon and a new chief executive officer are the winning combination needed to bring its lead drug candidate to market. ReNetX Bio is looking to guide its drug candidate, Nogo Trap, through its first round of clinical trials. Company officials say Nogo Trap is designed to help patients with chronic spinal cord injury. Read More
Yale Discovery - And Startup - Provide Hope for those with Spinal Cord Injury
NEW HAVEN, Conn., July 24, 2017 -- Yale neurology and neuroscience professor Stephen Strittmatter has made a discovery that has long eluded researchers—how to regrow damaged nerve fibers after an injury. If effective—and animal studies show real promise—the discovery would provide doctors a way to treat what has thus far been untreatable—spinal cord injury. Read More
Company Appoints Erika R. Smith as CEO; Previously Director at Yale Innovation Fund
Initiates Series A Financing Round to Fund Clinical Trial in Chronic Spinal Cord Injury
NEW HAVEN, Conn., July 24, 2017 (GLOBE NEWSWIRE) -- ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, today announced its launch as a new company with the appointment of Erika Smith as Chief Executive Officer. The company also announced the initiation of a Series A financing round to fund its first clinical trial of its lead therapeutic candidate, Nogo Trap, in patients with chronic spinal cord injury. Read More